Uppsala, Sweden, June 1, 2026. Dicot Pharma has been granted a new patent in Japan for the active substance in LIB-01. The patent strengthens the intellectual property of the company’s drug candidate in a significant market until 2043.
The Japan Patent Office, JPO, has granted to a new Composition of Matter patent for the active substance in Dicot Pharma’s drug candidate LIB-01, which is valid to 2043.
Corresponding patents have previously been approved in the US and applications are pending in other relevant countries.
“We are pursuing an active patent strategy, with already granted patents in several key markets. The new patent in Japan provides broad and robust protection for LIB-01 in yet another large and important market for novel treatments against erectile dysfunction. In addition to this, several new patent applications have been submitted to further strengthen the global protection for LIB-01,” says Dicot Pharma’s CEO, Elin Trampe.